Bharat Biotech asked to submit complete phase 2 data of its Covid-19 vaccine before phase 3 trial

Bharat Biotech, which had sought DCGI's nod for conducting phase-3 clinical trials of its Covid-19 vaccine candidate, has been asked to submit complete safety and immunogenicity data of the ongoing phase-2 trial, besides providing some clarifications, before proceeding for the next stage.